Trétinoïne : interactions médicamenteuses

Avoid concomitant use of tretinoin capsules and anti-fibrinolytic agents, such as tranexamic acid, aminocaproic acid or aprotinin [see Drug Interactions ( 7.4 )] . (notice Trétinoïne, Mises en garde et précautions)

Avoid concomitant use of tretinoin capsules and anti-fibrinolytic agents, such as tranexamic acid, aminocaproic acid or aprotinin [see Drug Interactions ( 7.4 )] . (notice Trétinoïne, Mises en garde et précautions)

Tretinoin capsules are contraindicated in patients with a known hypersensitivity to tretinoin capsules, any of its components, or other retinoids. (notice Trétinoïne, Contre-indications)

Tretinoin capsules are contraindicated in patients with a known hypersensitivity to tretinoin capsules, any of its components, or other retinoids. (notice Trétinoïne, Contre-indications)

• Strong CYP3A Inhibitors and Inducers: Avoid coadministration with strong CYP3A inhibitors and inducers. (notice Trétinoïne, Interactions médicamenteuses)

• Strong CYP3A Inhibitors and Inducers: Avoid coadministration with strong CYP3A inhibitors and inducers. (notice Trétinoïne, Interactions médicamenteuses)

Avoid concomitant use with strong CYP3A inducers if possible. (notice Trétinoïne, Interactions médicamenteuses)

• Strong CYP3A Inhibitors and Inducers: Avoid coadministration with strong CYP3A inhibitors and inducers. (notice Trétinoïne, Interactions médicamenteuses)

At first signs or symptoms of this syndrome, immediately initiate high-dose corticosteroid therapy and hemodynamic monitoring until resolution of signs and symptoms. (notice Trétinoïne, Mise en garde encadrée)

At first signs or symptoms of this syndrome, immediately initiate high-dose corticosteroid therapy and hemodynamic monitoring until resolution of signs and symptoms. (notice Trétinoïne, Mise en garde encadrée)

At first signs or symptoms of this syndrome, immediately initiate high-dose corticosteroid therapy and hemodynamic monitoring until resolution of signs and symptoms. (notice Trétinoïne, Mise en garde encadrée)

Tretinoin capsules are contraindicated in patients with a known hypersensitivity to tretinoin capsules, any of its components, or other retinoids. (notice Trétinoïne, Contre-indications)

Avoid concomitant use with strong CYP3A inducers if possible. (notice Trétinoïne, Interactions médicamenteuses)

At first signs or symptoms of this syndrome, immediately initiate high-dose corticosteroid therapy and hemodynamic monitoring until resolution of signs and symptoms. (notice Trétinoïne, Mise en garde encadrée)

At first signs or symptoms of this syndrome, immediately initiate high-dose corticosteroid therapy and hemodynamic monitoring until resolution of signs and symptoms. (notice Trétinoïne, Mise en garde encadrée)

Avoid concomitant use with strong CYP3A inducers if possible. (notice Trétinoïne, Interactions médicamenteuses)

• Strong CYP3A Inhibitors and Inducers: Avoid coadministration with strong CYP3A inhibitors and inducers. (notice Trétinoïne, Interactions médicamenteuses)

At first signs or symptoms of this syndrome, immediately initiate high-dose corticosteroid therapy and hemodynamic monitoring until resolution of signs and symptoms. (notice Trétinoïne, Mise en garde encadrée)

• Strong CYP3A Inhibitors and Inducers: Avoid coadministration with strong CYP3A inhibitors and inducers. (notice Trétinoïne, Interactions médicamenteuses)

• Strong CYP3A Inhibitors and Inducers: Avoid coadministration with strong CYP3A inhibitors and inducers. (notice Trétinoïne, Interactions médicamenteuses)

• Strong CYP3A Inhibitors and Inducers: Avoid coadministration with strong CYP3A inhibitors and inducers. (notice Trétinoïne, Interactions médicamenteuses)

Avoid concomitant use with strong CYP3A inducers if possible. (notice Trétinoïne, Interactions médicamenteuses)

At first signs or symptoms of this syndrome, immediately initiate high-dose corticosteroid therapy and hemodynamic monitoring until resolution of signs and symptoms. (notice Trétinoïne, Mise en garde encadrée)

• Strong CYP3A Inhibitors and Inducers: Avoid coadministration with strong CYP3A inhibitors and inducers. (notice Trétinoïne, Interactions médicamenteuses)

• Strong CYP3A Inhibitors and Inducers: Avoid coadministration with strong CYP3A inhibitors and inducers. (notice Trétinoïne, Interactions médicamenteuses)

Avoid concomitant use with strong CYP3A inducers if possible. (notice Trétinoïne, Interactions médicamenteuses)

At first signs or symptoms of this syndrome, immediately initiate high-dose corticosteroid therapy and hemodynamic monitoring until resolution of signs and symptoms. (notice Trétinoïne, Mise en garde encadrée)

At first signs or symptoms of this syndrome, immediately initiate high-dose corticosteroid therapy and hemodynamic monitoring until resolution of signs and symptoms. (notice Trétinoïne, Mise en garde encadrée)

At first signs or symptoms of this syndrome, immediately initiate high-dose corticosteroid therapy and hemodynamic monitoring until resolution of signs and symptoms. (notice Trétinoïne, Mise en garde encadrée)

• Strong CYP3A Inhibitors and Inducers: Avoid coadministration with strong CYP3A inhibitors and inducers. (notice Trétinoïne, Interactions médicamenteuses)

• Strong CYP3A Inhibitors and Inducers: Avoid coadministration with strong CYP3A inhibitors and inducers. (notice Trétinoïne, Interactions médicamenteuses)

• Strong CYP3A Inhibitors and Inducers: Avoid coadministration with strong CYP3A inhibitors and inducers. (notice Trétinoïne, Interactions médicamenteuses)

• Strong CYP3A Inhibitors and Inducers: Avoid coadministration with strong CYP3A inhibitors and inducers. (notice Trétinoïne, Interactions médicamenteuses)

• Strong CYP3A Inhibitors and Inducers: Avoid coadministration with strong CYP3A inhibitors and inducers. (notice Trétinoïne, Interactions médicamenteuses)

• Strong CYP3A Inhibitors and Inducers: Avoid coadministration with strong CYP3A inhibitors and inducers. (notice Trétinoïne, Interactions médicamenteuses)

Avoid concomitant use with strong CYP3A inducers if possible. (notice Trétinoïne, Interactions médicamenteuses)

Avoid concomitant use with strong CYP3A inducers if possible. (notice Trétinoïne, Interactions médicamenteuses)

• Strong CYP3A Inhibitors and Inducers: Avoid coadministration with strong CYP3A inhibitors and inducers. (notice Trétinoïne, Interactions médicamenteuses)

• Strong CYP3A Inhibitors and Inducers: Avoid coadministration with strong CYP3A inhibitors and inducers. (notice Trétinoïne, Interactions médicamenteuses)

At first signs or symptoms of this syndrome, immediately initiate high-dose corticosteroid therapy and hemodynamic monitoring until resolution of signs and symptoms. (notice Trétinoïne, Mise en garde encadrée)

At first signs or symptoms of this syndrome, immediately initiate high-dose corticosteroid therapy and hemodynamic monitoring until resolution of signs and symptoms. (notice Trétinoïne, Mise en garde encadrée)

At first signs or symptoms of this syndrome, immediately initiate high-dose corticosteroid therapy and hemodynamic monitoring until resolution of signs and symptoms. (notice Trétinoïne, Mise en garde encadrée)

At first signs or symptoms of this syndrome, immediately initiate high-dose corticosteroid therapy and hemodynamic monitoring until resolution of signs and symptoms. (notice Trétinoïne, Mise en garde encadrée)

At first signs or symptoms of this syndrome, immediately initiate high-dose corticosteroid therapy and hemodynamic monitoring until resolution of signs and symptoms. (notice Trétinoïne, Mise en garde encadrée)

• Strong CYP3A Inhibitors and Inducers: Avoid coadministration with strong CYP3A inhibitors and inducers. (notice Trétinoïne, Interactions médicamenteuses)

• Strong CYP3A Inhibitors and Inducers: Avoid coadministration with strong CYP3A inhibitors and inducers. (notice Trétinoïne, Interactions médicamenteuses)

Avoid concomitant use with strong CYP3A inducers if possible. (notice Trétinoïne, Interactions médicamenteuses)

Avoid concomitant use with strong CYP3A inducers if possible. (notice Trétinoïne, Interactions médicamenteuses)

At first signs or symptoms of this syndrome, immediately initiate high-dose corticosteroid therapy and hemodynamic monitoring until resolution of signs and symptoms. (notice Trétinoïne, Mise en garde encadrée)

At first signs or symptoms of this syndrome, immediately initiate high-dose corticosteroid therapy and hemodynamic monitoring until resolution of signs and symptoms. (notice Trétinoïne, Mise en garde encadrée)

• Leukocytosis: Consider administering cytoreductive chemotherapy (including an anthracycline if not contraindicated or hydroxyurea) with tretinoin capsules in the setting of leukocytosis, as clinically indicated. (notice Trétinoïne, Mises en garde et précautions)

• Strong CYP3A Inhibitors and Inducers: Avoid coadministration with strong CYP3A inhibitors and inducers. (notice Trétinoïne, Interactions médicamenteuses)

• Strong CYP3A Inhibitors and Inducers: Avoid coadministration with strong CYP3A inhibitors and inducers. (notice Trétinoïne, Interactions médicamenteuses)

Tretinoin capsules are contraindicated in patients with a known hypersensitivity to tretinoin capsules, any of its components, or other retinoids. (notice Trétinoïne, Contre-indications)

• Strong CYP3A Inhibitors and Inducers: Avoid coadministration with strong CYP3A inhibitors and inducers. (notice Trétinoïne, Interactions médicamenteuses)

• Strong CYP3A Inhibitors and Inducers: Avoid coadministration with strong CYP3A inhibitors and inducers. (notice Trétinoïne, Interactions médicamenteuses)

• Strong CYP3A Inhibitors and Inducers: Avoid coadministration with strong CYP3A inhibitors and inducers. (notice Trétinoïne, Interactions médicamenteuses)

• Strong CYP3A Inhibitors and Inducers: Avoid coadministration with strong CYP3A inhibitors and inducers. (notice Trétinoïne, Interactions médicamenteuses)

• Strong CYP3A Inhibitors and Inducers: Avoid coadministration with strong CYP3A inhibitors and inducers. (notice Trétinoïne, Interactions médicamenteuses)

Avoid concomitant use with strong CYP3A inducers if possible. (notice Trétinoïne, Interactions médicamenteuses)

At first signs or symptoms of this syndrome, immediately initiate high-dose corticosteroid therapy and hemodynamic monitoring until resolution of signs and symptoms. (notice Trétinoïne, Mise en garde encadrée)

• Strong CYP3A Inhibitors and Inducers: Avoid coadministration with strong CYP3A inhibitors and inducers. (notice Trétinoïne, Interactions médicamenteuses)

Avoid concomitant use of isotretinoin and EMROSI because isotretinoin, a systemic retinoid, is also known to cause idiopathic intracranial hypertension. (notice Minocycline, Mises en garde et précautions)

• Strong CYP3A Inhibitors and Inducers: Avoid coadministration with strong CYP3A inhibitors and inducers. (notice Trétinoïne, Interactions médicamenteuses)

Avoid concomitant use with strong CYP3A inducers if possible. (notice Trétinoïne, Interactions médicamenteuses)

Avoid concomitant use with strong CYP3A inducers if possible. (notice Trétinoïne, Interactions médicamenteuses)

Avoid concomitant use with strong CYP3A inducers if possible. (notice Trétinoïne, Interactions médicamenteuses)

At first signs or symptoms of this syndrome, immediately initiate high-dose corticosteroid therapy and hemodynamic monitoring until resolution of signs and symptoms. (notice Trétinoïne, Mise en garde encadrée)

Avoid concomitant use with strong CYP3A inducers if possible. (notice Trétinoïne, Interactions médicamenteuses)

• Strong CYP3A Inhibitors and Inducers: Avoid coadministration with strong CYP3A inhibitors and inducers. (notice Trétinoïne, Interactions médicamenteuses)

Avoid concomitant use with strong CYP3A inducers if possible. (notice Trétinoïne, Interactions médicamenteuses)

• Strong CYP3A Inhibitors and Inducers: Avoid coadministration with strong CYP3A inhibitors and inducers. (notice Trétinoïne, Interactions médicamenteuses)

At first signs or symptoms of this syndrome, immediately initiate high-dose corticosteroid therapy and hemodynamic monitoring until resolution of signs and symptoms. (notice Trétinoïne, Mise en garde encadrée)

Avoid concomitant use with strong CYP3A inducers if possible. (notice Trétinoïne, Interactions médicamenteuses)

• Strong CYP3A Inhibitors and Inducers: Avoid coadministration with strong CYP3A inhibitors and inducers. (notice Trétinoïne, Interactions médicamenteuses)

• Strong CYP3A Inhibitors and Inducers: Avoid coadministration with strong CYP3A inhibitors and inducers. (notice Trétinoïne, Interactions médicamenteuses)

Avoid concomitant use with strong CYP3A inducers if possible. (notice Trétinoïne, Interactions médicamenteuses)

Avoid concomitant use with strong CYP3A inducers if possible. (notice Trétinoïne, Interactions médicamenteuses)

Avoid concomitant use with strong CYP3A inducers if possible. (notice Trétinoïne, Interactions médicamenteuses)

• Strong CYP3A Inhibitors and Inducers: Avoid coadministration with strong CYP3A inhibitors and inducers. (notice Trétinoïne, Interactions médicamenteuses)

At first signs or symptoms of this syndrome, immediately initiate high-dose corticosteroid therapy and hemodynamic monitoring until resolution of signs and symptoms. (notice Trétinoïne, Mise en garde encadrée)

At first signs or symptoms of this syndrome, immediately initiate high-dose corticosteroid therapy and hemodynamic monitoring until resolution of signs and symptoms. (notice Trétinoïne, Mise en garde encadrée)

Avoid concomitant use with strong CYP3A inducers if possible. (notice Trétinoïne, Interactions médicamenteuses)

• Strong CYP3A Inhibitors and Inducers: Avoid coadministration with strong CYP3A inhibitors and inducers. (notice Trétinoïne, Interactions médicamenteuses)

Avoid concomitant use with strong CYP3A inducers if possible. (notice Trétinoïne, Interactions médicamenteuses)

Avoid concomitant use with strong CYP3A inducers if possible. (notice Trétinoïne, Interactions médicamenteuses)

Avoid concomitant use with strong CYP3A inducers if possible. (notice Trétinoïne, Interactions médicamenteuses)

• Strong CYP3A Inhibitors and Inducers: Avoid coadministration with strong CYP3A inhibitors and inducers. (notice Trétinoïne, Interactions médicamenteuses)

• Strong CYP3A Inhibitors and Inducers: Avoid coadministration with strong CYP3A inhibitors and inducers. (notice Trétinoïne, Interactions médicamenteuses)

Avoid concomitant use with strong CYP3A inducers if possible. (notice Trétinoïne, Interactions médicamenteuses)

Concomitant use of isotretinoin and tetracycline should be avoided because isotretinoin, a systemic retinoid, is also known to cause pseudotumor cerebri. (notice Tétracycline, Mises en garde)

• Strong CYP3A Inhibitors and Inducers: Avoid coadministration with strong CYP3A inhibitors and inducers. (notice Trétinoïne, Interactions médicamenteuses)

Avoid concomitant use with strong CYP3A inducers if possible. (notice Trétinoïne, Interactions médicamenteuses)

At first signs or symptoms of this syndrome, immediately initiate high-dose corticosteroid therapy and hemodynamic monitoring until resolution of signs and symptoms. (notice Trétinoïne, Mise en garde encadrée)

• Strong CYP3A Inhibitors and Inducers: Avoid coadministration with strong CYP3A inhibitors and inducers. (notice Trétinoïne, Interactions médicamenteuses)

• Strong CYP3A Inhibitors and Inducers: Avoid coadministration with strong CYP3A inhibitors and inducers. (notice Trétinoïne, Interactions médicamenteuses)

Drugs That Increase the Risk of Hypercalcemia Increase frequency of monitoring of calcium concentrations in patients taking concomitant Calcium Chloride Injection and other drugs that increase the risk of hypercalcemia (e.g., calcipotriene, estrogen, lithium, parathyroid hormone, teriparatide, thiazide diuretics, Vitamin A, and Vitamin D). (notice Chlorure de calcium, Interactions médicamenteuses)

The concomitant use of other products (e.g., tetracyclines) that can cause intracranial hypertension may increase the risk. (notice Trétinoïne, Mises en garde et précautions)

The concomitant use of other products (e.g., tetracyclines) that can cause intracranial hypertension may increase the risk. (notice Trétinoïne, Mises en garde et précautions)

Patients with elevated vitamin A levels may be at increased risk. (notice Élexacaftor, tézacaftor et ivacaftor, Mises en garde et précautions)

Monitor patients receiving XATMEP with other potential hepatotoxins (e.g., azathioprine, retinoids, and sulfasalazine) for possible signs of hepatotoxicity. (notice Méthotrexate, Interactions médicamenteuses)

The effect of ORLISTAT on the absorption of supplemental vitamin D, vitamin A, and nutritionally-derived vitamin K is not known at this time [see Clinical Pharmacology (12.3) , and Warnings and Precautions (5.1) ] . (notice Orlistat, Interactions médicamenteuses)

The concomitant use of other products (e.g., tetracyclines) that can cause intracranial hypertension may increase the risk. (notice Trétinoïne, Mises en garde et précautions)

The concomitant use of other products (e.g., tetracyclines) that can cause intracranial hypertension may increase the risk. (notice Trétinoïne, Mises en garde et précautions)

Hepatotoxicity: Elevated aspartate aminotransferase (AST), alkaline phosphatase and serum bilirubin have occurred in patients with newly-diagnosed low-risk APL treated with arsenic trioxide in combination with tretinoin. (notice Trioxyde d'arsenic, Mises en garde et précautions)

Drugs that may cause hypercalcemia: Vitamin D, vitamin A, thiazide diuretics, estrogen, calcipotriene and teriparatide administration may cause hypercalcemia. (notice Gluconate de calcium, Interactions médicamenteuses)